NantKwest’s Vax-DC/MM cell therapy has induced a partial or complete response in 42 percent of relapsed or refractory multiple myeloma (MM)…
Articles by Joana Fernandes, PhD
Dragonfly Therapeutics and Celgene have teamed up to develop therapies for multiple myeloma and other blood cancers. The partners…
Genmab announced that its partner Janssen Biotech will launch three novel studies to investigate the effect of Darzalex…
Switzerland’s Agency for Therapeutic Products (Swissmedic) has awarded PharmaMar’s Aplidin orphan drug status to treat patients with multiple myeloma, following a similar…
Combination treatment with Velcade (bortezomib) and Thalomid (thalidomide) may significantly improve survival of multiple myeloma patients who received a stem…
Early treatment with a combination of anti-cancer drugs in patients with smoldering myeloma, who are at high risk of developing…
Genentech will present results on several approved or investigational therapies for blood cancers, including lymphoma and myeloma, in the…
Understanding how multiple myeloma develops and responds to therapies may be easier using a new mouse model developed at Yale…
PharmaMar has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the use of Aplidin (plitidepsin) in…
The Multiple Myeloma Research Foundation (MMRF) and the Memorial Sloan Kettering Cancer Center are collaborating to launch a…